Few prognostic factors have been identified and successfully replicated for patients with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC). However, a new report has shown that alkaline phosphatase velocity (APV) is an independent predictor of bone-metastasis-free survival and overall survival in patients with nmCRPC.